Generics 4

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Alogliptin manufacturers

4 products found

Filters

Filters

Filters , active

Country of origin : India

Clear all

4 products found

alogliptin

Tablets 6.25 mg, 12.5 mg, 25 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Manufacturer #10627

Manufacturer usually replies in 8 days

alogliptin + metformin

Tablets 12.5mg+850mg, 12.5mg+1000mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Manufacturer #13291
This pharmaceutical company is a leading global provider of affordable medications, with a strong focus on API development, formulation development, and CRAMS (contract research and manufacturing services). They have extensive experience in oncology and boast a portfolio exceeding 50 "first-to-file" ANDAs. The company operates across multiple regions, including Asia, Europe, Africa, the Middle East, and North America, with production lines encompassing prescription medications, over-the-counter drugs, and APIs. They hold numerous GMP certifications and product patents, highlighting their commitment to quality and innovation. Key therapy areas include oncology and other complex drug development segments.

Manufacturer usually replies in 6 days

alogliptin

Tablets 6.25mg, 12.5mg, 25mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
India
GMP approvals
EU GMP
Manufacturer #13291
This pharmaceutical company is a leading global provider of affordable medications, with a strong focus on API development, formulation development, and CRAMS (contract research and manufacturing services). They have extensive experience in oncology and boast a portfolio exceeding 50 "first-to-file" ANDAs. The company operates across multiple regions, including Asia, Europe, Africa, the Middle East, and North America, with production lines encompassing prescription medications, over-the-counter drugs, and APIs. They hold numerous GMP certifications and product patents, highlighting their commitment to quality and innovation. Key therapy areas include oncology and other complex drug development segments.

Manufacturer usually replies in 6 days

Want to see all 4 products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription
Alogliptin is to lower blood sugar levels in patients with type 2 diabetes, a condition in which blood sugar is too high because the body does not produce or use insulin normally. It is used in conjunction with prescribed diet and exercises. However, Alogliptin is not used to treat type 1 diabetes or diabetic ketoacidosis. Like other members of it family of drugs, patients using Alogliptin gain little or no weight, and has relatively modest glucose-lowering ability. Over time, Diabetics develop life-threatening conditions or complications like heart diseases, and stroke, kidney issues, nerve damage, and eye problems. Alogliptin therapy decreases the odds of suffering a heart attack or stroke, or diabetes-caused ailments like kidney failure, nerve damage leading to numbness, cold feet and decreased libido in men and women and eye problems, including loss of vision, or even gum disease. Alogliptin is sold under the brand name Nesina® amongst others. Other brand names with combination products include Kazano® (containing Alogliptin, Metformin) and Oseni® (containing Alogliptin, Pioglitazone). Takeda Pharmaceutical Company submitted a New Drug Application (NDA) to USFDA in December 2007. After success in positive results from Phase III clinical trials, in September 2008, Takeda Pharmaceutical also filed for approval in Japan winning approval in April 2010. The first USFDA NDA did not get approval and was followed by a pair of NDAs but in 2012, they did not get the approval citing insufficient evidence. How much will I take? Alogliptin is sold as tablets in the increasing strength of 25mg, 12.5mg or 6.25mg tablets. The usual dose prescribed for adults is 25mg a day. For patients also suffering from kidney isssues, the dosage is kept low at 12.5 mg or even 6.25 mg/day. The price of Alogliptin Patients can buy a Nesina oral tablet 6.25 mg costs around $300- $424 for a supply of 30 tablets that is $14 per tablet at the higher end. The cost of Alogliptin varies hugely around the world with as low as $5 per the same tablet. The cost of Alogliptin is in general lower in the developing world compared to the developed countries. How does it work? Alogliptin is in a class of medications called dipeptidyl peptidase-4 inhibitors. Alogliptin works by increasing the amount of insulin that body cannot make. Insulin is the hormone that controls sugar levels in blood. Alogliptin inhibits the incretins, thus increasing the amount of active plasma incretins, which in turn helps regain glycemic control. Finding Alogliptin Manufacturers and Suppliers: The process of finding trusted Alogliptin manufacturers and Alogliptin suppliers can be made quicker and more accessible by using Pipelinepharma's online platform, a B2B marketplace that lets you finalize the deals of pharmaceutical products in a matter of a few clicks. Also, it is an easy to use online platform to grow your business opportunities. The robust search engine makes it convenient to search for manufacturers and suppliers of Alogliptin. The search can be further refined with industry-specific filters such as dossier type, country of origin, GMP approvals, and search criteria for Wholesaler, etc. helping to get in contact with the preferred manufacturer and supplier readily. Makers Takeda Pharmaceuticals America, Inc. Perrigo New York Inc Aphena Pharma Solutions - Tennessee, LLC Brand names: Nesina, Vipidia; Kazano, Vipidomet (with metformin); Oseni, Incresync (with pioglitazone)

Interested in becoming a subscriber?

Please provide the following information to receive an offer tailored to your business needs

  1. Number of company users for the subscription
  2. The rough number of products you would like to source in the 12 months
  3. Target market(s) for commercialisation